CAMP4 Therapeutics (NASDAQ:CAMP) CEO Buys $10,809.15 in Stock

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) CEO Josh Mandel-Brehm acquired 6,551 shares of CAMP4 Therapeutics stock in a transaction dated Monday, August 3rd. The shares were bought at an average cost of $1.65 per share, with a total value of $10,809.15. Following the transaction, the chief executive officer owned 284,968 shares in the company, valued at approximately $470,197.20. This trade represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CAMP4 Therapeutics Stock Down 5.8%

CAMP4 Therapeutics stock opened at $4.24 on Friday. CAMP4 Therapeutics Corporation has a 12-month low of $1.32 and a 12-month high of $7.75. The firm’s fifty day moving average is $4.02 and its 200 day moving average is $4.30. The company has a market capitalization of $220.18 million, a PE ratio of -1.80 and a beta of 0.22.

CAMP4 Therapeutics (NASDAQ:CAMP) last issued its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million for the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. Sell-side analysts expect that CAMP4 Therapeutics Corporation will post -0.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CAMP. Chardan Capital set a $6.50 price objective on shares of CAMP4 Therapeutics and gave the company a “buy” rating in a report on Wednesday, June 10th. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Rodman & Renshaw started coverage on CAMP4 Therapeutics in a research report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price for the company. Zacks Research downgraded CAMP4 Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 15th. Finally, JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, CAMP4 Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $8.36.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CAMP. Bank of America Corp DE bought a new stake in shares of CAMP4 Therapeutics during the fourth quarter worth about $86,000. Bridgeway Capital Management LLC acquired a new position in CAMP4 Therapeutics during the 2nd quarter valued at about $36,000. Two Sigma Investments LP acquired a new position in CAMP4 Therapeutics during the 3rd quarter valued at about $292,000. Vivo Capital LLC bought a new stake in CAMP4 Therapeutics during the 3rd quarter worth approximately $11,765,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in CAMP4 Therapeutics during the 4th quarter worth approximately $61,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.